Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus

BACKGROUND AND OBJECTIVES: Sifalimumab is a fully human immunoglobulin G1κ monoclonal antibody that binds to and neutralizes a majority of the subtypes of human interferon-α. Sifalimumab is being evaluated as a treatment for systemic lupus erythematosus (SLE). The primary objectives of this analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Narwal, Rajesh, Roskos, Lorin K., Robbie, Gabriel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824374/
https://www.ncbi.nlm.nih.gov/pubmed/23754736
http://dx.doi.org/10.1007/s40262-013-0085-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824374/
https://www.ncbi.nlm.nih.gov/pubmed/23754736
http://dx.doi.org/10.1007/s40262-013-0085-2

Ejemplares similares